These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16344424)

  • 1. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia.
    Chim CS; Kwong YL; Lie AK; Ma SK; Chan CC; Wong LG; Kho BC; Lee HK; Sim JP; Chan CH; Chan JC; Yeung YM; Law M; Liang R
    Arch Intern Med; 2005 Dec 12-26; 165(22):2651-8. PubMed ID: 16344424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.
    Passamonti F; Rumi E; Arcaini L; Boveri E; Elena C; Pietra D; Boggi S; Astori C; Bernasconi P; Varettoni M; Brusamolino E; Pascutto C; Lazzarino M
    Haematologica; 2008 Nov; 93(11):1645-51. PubMed ID: 18790799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A; Barbui T
    Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Björkholm M; Hultcrantz M; Derolf ÅR
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
    Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
    Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia and myelofibrosis: Simultaneous transformation of essential thrombocythemia during treatment with hydroxyurea.
    Nalluru SS; Efe O; Chen Y; Trivedi N
    J Cancer Res Ther; 2022; 18(4):1180-1182. PubMed ID: 36149183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Soyer N; Haznedaroğlu İC; Cömert M; Çekdemir D; Yılmaz M; Ünal A; Çağlıyan G; Bilgir O; İlhan O; Özdemirkıran F; Kaya E; Şahin F; Vural F; Saydam G
    Turk J Haematol; 2017 Mar; 34(1):27-33. PubMed ID: 27094252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
    Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
    Godfrey AL; Campbell PJ; MacLean C; Buck G; Cook J; Temple J; Wilkins BS; Wheatley K; Nangalia J; Grinfeld J; McMullin MF; Forsyth C; Kiladjian JJ; Green AR; Harrison CN; ; ; ;
    J Clin Oncol; 2018 Dec; 36(34):3361-3369. PubMed ID: 30153096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.
    Hsiao HH; Ito Y; Sashida G; Ohyashiki JH; Ohyashiki K
    Leuk Res; 2005 Nov; 29(11):1247-52. PubMed ID: 16164981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
    Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
    Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N
    Am J Hematol; 2009 Apr; 84(4):215-20. PubMed ID: 19208420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When and how to treat essential thrombocythemia.
    Barbui T; Finazzi G
    N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.